Navigation Links
Cadence Pharmaceuticals Reports First Quarter 2009 Financial Results
Date:5/7/2009

arter of 2008, there is a lack of comparability in the per share amounts between the 2009 and 2008 periods presented.

                          CADENCE PHARMACEUTICALS, INC.
                          (a development stage company)
                             CONDENSED BALANCE SHEETS

                                                     March 31,   December 31,
                                                       2009          2008
                                                   (unaudited)
                      Assets
    Current assets:
      Cash and cash equivalents
                                                  $118,549,004   $47,627,246
      Restricted cash                                1,847,848     2,195,696
      Prepaid expenses and other current assets        312,801       219,674
        Total current assets                       120,709,653    50,042,616

    Property and equipment, net                      4,376,590     4,477,020
    Restricted cash                                    537,586       537,586
    Other assets                                        57,673        90,792
        Total assets                              $125,681,502   $55,148,014

            Liabilities and Stockholders' Equity
    Current liabilities:
      Accounts payable                              $3,542,647    $4,877,854
      Accrued liabilities                            5,814,540     9,063,310
      Current portion of long-term debt              7,045,605     7,694,173
      Current current liabilities                       22,048        22,048
        Total current liabilities                   16,424,840    21,657,385

    Deferred rent                                      876,724       952,274
    Long-term debt, less current portion and
     discount                                        4,653,728     6,098,113
    Total stockholders' equity                     103,726,210    26,44
'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Two Investment Conferences During the Month of May 2009
2. Cadence Pharmaceuticals Announces Presentations at Upcoming Scientific Conferences
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BioCentury Publications Inc. Future Leaders in the Biotech Industry Conference in New York on April 2, 2009
4. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2008 Financial Results and Corporate Update on March 12, 2009
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2008 Financial Results and Provide a Clinical Program Update on November 6, 2008
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the BIOCOM Investor Conference
8. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the JMP Securities Third Annual Healthcare Focus Conference
9. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
10. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Two Investment Conferences During the Month of August 2008
11. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at the Leerink Swann Pain Roundtable Conference on June 23, 2008 in New York
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Hills, NY (PRWEB) August 29, 2014 ... Burnt Hills Veterinary Hospital are seeking candidates to participate ... dogs with osteoarthritis. The ultimate goal of this ... donor stem cells into one or two arthritically affected ... treated joints. , Candidates for the current investigational ...
(Date:8/29/2014)... Boston, MA, San Antonio, TX (PRWEB) August 29, ... audited, ISO 9001:2008 and ISO 13485:2003 certified, GAMP® ... it has been awarded an international Phase II ... patients with non-Hodgkin’s lymphoma. , Throughout this trial, ... services including, but not limited to, protocol and ...
(Date:8/28/2014)... “This kit has an improved extraction efficiency and provides ... ppb,” said Mark Tess, PhD, Mycotoxin Product Manager for Charm ... and USDA-GIPSA inspection agencies that have a need to detect ... in a matter of minutes with nothing but our equipment ... and grain before accepting it, but they no longer have ...
(Date:8/28/2014)... Willow Grove, PA (PRWEB) August 28, 2014 ... talent, and create a culture that will allow individuals ... that are becoming increasingly important for employers looking to ... life science industries are embracing this trend, as the ... the fabric of a company, which will have real ...
Breaking Biology Technology:Burnt Hills Veterinary Hospital Seeks Candidates for an Investigational Study of Stem Cells for Dogs with Arthritis 2Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 2Klein Hersh International Leads Philadelphia Area Life Science Industry in Company Culture 3
... Genzyme Products, CAMBRIDGE, Mass., Sept. 18 Genzyme ... significant expansion of its,flagship manufacturing facility at Allston Landing ... space for manufacturing support,functions, and will allow for the ... by a ceremony featuring Massachusetts Governor,Deval L. Patrick, Boston ...
... - the New ISI Web of Knowledge - to ... Throughout the Country, PHILADELPHIA and LONDON, Sept. 18 ... TOC ; TSX: TOC) and,leading provider of information solutions ... Spain,s La Fundacion Espanola,para la Ciencia y la Tecnologia ...
... GSK Increases Research Effort to Target Drug-Resistant Gram Negative ... ... GlaxoSmithKline (NYSE:,GSK) today announced that it has signed an agreement ... Defense (DOD), to,identify and develop a new class of antibacterials targeting ...
Cached Biology Technology:Genzyme Begins Major Expansion of Boston Manufacturing Facility 2Genzyme Begins Major Expansion of Boston Manufacturing Facility 3Genzyme Begins Major Expansion of Boston Manufacturing Facility 4Genzyme Begins Major Expansion of Boston Manufacturing Facility 5Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 2Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge 3GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program 2GlaxoSmithKline Awarded U.S. Department of Defense Contract to Pursue Novel Antibacterial Research Program 3
(Date:8/28/2014)... (ESA) is pleased to announce the selection of Dr. ... Honorary Membership acknowledges those who have served ESA for ... affairs of the Society that has reached an extraordinary ... ESA Governing Board and then voted on by the ... Awards Ceremony at Entomology 2014, ESA,s Annual Meeting in ...
(Date:8/28/2014)... expansion of marine protected areas is needed to protect ... to investigators from the Wildlife Conservation Society and other ... saving the largest numbers of species, often at the ... ecological functions. , Many vital ecological functions ... also are food for millions of people. This ...
(Date:8/28/2014)... healthier for your neighbors than traditional cigarettes, but ... a new study from USC. , Scientists studying ... decrease in exposure to harmful particles, with close-to-zero ... to some harmful metals in second-hand e-cigarette smoke ... tobacco smoke contains high levels of polycyclic aromatic ...
Breaking Biology News(10 mins):Fred Baxendale selected as Honorary Member of the Entomological Society of America 2Study finds marine protected areas inadequate for protecting fish and ocean ecology 2Second-hand e-cig smoke compared to regular cigarette smoke 2
... Miami Beach, FL (March 5, 2010) Research presented ... Annual Meeting of the American Academy of Dermatology (Miami ... multiple perspectives, offering insights into how ingredient formulations, care ... are on display, discussing a wide range of topics, ...
... Genetics Society of America is pleased to announce the ... 1, 2010, at the University of British Columbia (UBC) ... investigators studying various aspects of eukaryotic biology in yeast. ... and a Canadian astronaut who is also a Member ...
... discovered a key reason why a form of leukemia ... phase called blast crisis. The study, led by cancer ... G. James Cancer Hospital and Richard J. Solove Research ... when immature white blood cells lose a molecule called ...
Cached Biology News:P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 2P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 3P&G Beauty & Grooming presents advancements in skin care at AAD Annual Meeting 42010 Yeast Genetics and Molecular Biology Meeting 22010 Yeast Genetics and Molecular Biology Meeting 3Study identifies key cause of chronic leukemia progression 2
... choice of PDMS Stamps (3 PDMS micropatterned ... micron squares or 100 um x 10 ... lines, 3 PDMS nano-patterned stamps with depth ... pitch of 400 nm, or 3 PDMS ...
Request Info...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Request Info...
Biology Products: